LTN Pharmaceuticals, Inc.
🇺🇸United States
Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Galeterone
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- LTN PHARMACEUTICALS, INC.
- Target Recruit Count
- 6
- Registration Number
- NCT02729376
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
- First Posted Date
- 2015-05-08
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- LTN PHARMACEUTICALS, INC.
- Target Recruit Count
- 953
- Registration Number
- NCT02438007
- Locations
- 🇪🇸
Hospital Clínic i Provincial de Barcelona-Oncology, Barcelona, Spain
🇪🇸Unidad Cnio Ibima de Investigacion en Prostata, Malaga, Spain
🇪🇸Hospital General Universitario Gregorio Marañón, Madrid, Spain
A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- LTN PHARMACEUTICALS, INC.
- Target Recruit Count
- 126
- Registration Number
- NCT01709734
- Locations
- 🇺🇸
UCLA David Geffen School of Medicine, Los Angeles, California, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸AAHS Research Institute, Annapolis, Maryland, United States
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
- First Posted Date
- 2009-08-17
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- LTN PHARMACEUTICALS, INC.
- Target Recruit Count
- 49
- Registration Number
- NCT00959959
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸UCLA, Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath